Crossmark

2-Hydroxybenzylamine (2-HOBA) to prevent early recurrence of atrial fibrillation after catheter ablation: protocol for a randomized controlled trial including detection of AF using a wearable device

Crossref DOI link: https://doi.org/10.1186/s13063-021-05553-6

Published Online: 2021-08-28

Published Print: 2021-12

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

O’Neill, Matthew J.

Yoneda, Zachary T.

Crawford, Diane M.

Ye, Fei

Ao, Mingfang

Pitchford, Lisa M.

Rathmacher, John A.

Murray, Katherine T.

Akers, Wendell S.

Roden, Dan M.

Michaud, Gregory F.

Shoemaker, M. Benjamin
Funding

Funding for this research was provided by:

American Heart Association (18SFRN34230132)
License Information

Text and Data Mining valid from 2021-08-28

Version of Record valid from 2021-08-28
More Information

Article History

Received: 17 November 2020

Accepted: 17 August 2021

First Online: 28 August 2021

Declarations

:

: The study protocol was approved by the Vanderbilt University Medical Center Institutional Review Board.

: N/A

: L.M. Pitchford and J. A. Rathmacher are employed by MTI Biotech, Inc., Ames, IA.

Document is current

Any future updates will be listed below